Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
GAITHERSBURG, Md., May 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S....
-
GAITHERSBURG, Md., April 16, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today...
-
GAITHERSBURG, Md., April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today...
-
GAITHERSBURG, Md., April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today...
-
Update on RSV F Vaccine Phase 3 Prepare™ trial for infants via maternal immunizationResults from Phase 1/2 trial of NanoFlu vaccine demonstrating improved immune responses compared to egg-based,...
-
RSV Phase 3 Prepare™ Trial Outcome De-risked by Successful Informational AnalysisNanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu VaccineJohn J. Trizzino...
-
GAITHERSBURG, Md., March 14, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the promotion of John J. Trizzino to Senior Vice President, Chief Business Officer (CBO) and Chief...
-
GAITHERSBURG, Md., March 07, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will provide a corporate update and report its fourth quarter and full year 2017 financial and...
-
Phase 2 trial of NanoFlu vaccine expected to begin in third quarter of 2018Given strength of trial data, Novavax has submitted detailed results for publication in peer-reviewed medical journal Company...
-
RSV F Vaccine informational analysis completed in fourth quarter of 2017RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrolleesFiling of RSV F Vaccine BLA anticipated by...